AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31369470 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Tone test condition (no alterations to lexical tones)
Number of subjects: 32
Study 31369470 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat Tone test condition (all tones changed to tone 1)
Number of subjects: 32
Study 31369470 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Tone test condition (random assignment of tones)
Number of subjects: 32
Study 31369470 — intervention group
Group type: COMPARATOR
Intervention: Cognitive function
Number of subjects: 32
Study 29784451 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy over 11 weeks with concomitant 5FU - hydroxyurea (VP-arm)
Number of subjects: 53
Study 29784451 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy (1.2 Gy twice daily) over 5 weeks with cetuximab (HFR-arm)
Number of subjects: 53
Study 29784451 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 53
Study 29784451 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicities and disease-free survival (DFS)
Number of subjects: 53
Study 27131588 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based laparoscopy curriculum
Number of subjects: 27
Study 27131588 — intervention group
Group type: COMPARATOR
Intervention: Conventional residency training
Number of subjects: 27
Study 23349402 — intervention group
Group type: EXPERIMENTAL
Intervention: New Perspectives
Number of subjects: 59
Study 23349402 — intervention group
Group type: COMPARATOR
Intervention: Transforming Your Life
Number of subjects: 59
Study 22507493 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose abdominal computed tomography (LDCT)
Number of subjects: 108
Study 22507493 — intervention group
Group type: COMPARATOR
Intervention: Plain abdominal radiography (AR)
Number of subjects: 108
Study 20624483 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 20624483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20624483 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18407467 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Val158Met genotype
Number of subjects: 130
Study 18652154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 30
Study 18652154 — intervention group
Group type: COMPARATOR
Intervention: Control group (children free of otolaryngological problems)
Number of subjects: 30
Study 15185427 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (11 microg twice weekly)
Number of subjects: 9
Study 11714065 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream, applied once daily for 7 days
Number of subjects: 117
Study 11714065 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream, applied once daily for 7 days
Number of subjects: 117
Study 9240592 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 102
Study 9240592 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 102
Study 8237866 — intervention group
Group type: EXPERIMENTAL
Intervention: Two FeSO4 tablets (100 mg Fe) daily
Number of subjects: 376
Study 8237866 — intervention group
Group type: EXPERIMENTAL
Intervention: One GDS capsule (50 mg Fe) daily
Number of subjects: 376
Study 8237866 — intervention group
Group type: COMPARATOR
Intervention: No iron supplement
Number of subjects: 376
Study 2897260 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1-29 (1 microgram/kg i.v.) in anorexia nervosa patients
Number of subjects: 14
Study 2897260 — intervention group
Group type: COMPARATOR
Intervention: GHRH 1-29 (1 microgram/kg i.v.) in normal controls
Number of subjects: 14
Study 2897260 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1-29 (1 microgram/kg i.v.) in tamoxifen-pretreated women
Number of subjects: 14
Study 2897260 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administration in all groups
Number of subjects: 14
Study 2897260 — intervention group
Group type: COMPARATOR
Intervention: GHRH administration in untreated control women
Number of subjects: 14
Study 31277060 — intervention group
Group type: COMPARATOR
Intervention: Conventional spine MRI
Number of subjects: 38
Study 31277060 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined conventional MRI and ZOOM‐EPI DTI
Number of subjects: 38
Study 31277060 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOOM‐EPI DTI
Number of subjects: 38
Study 31277060 — intervention group
Group type: EXPERIMENTAL
Intervention: Tractography
Number of subjects: 38
Study 27868466 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoxel honey lozenges
Number of subjects: 269
Study 27868466 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 269
Study 26012780 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with Staphylococcus epidermidis applied to the face twice per week for four weeks
Number of subjects: 0
Study 24265159 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administration of MTX/6MP
Number of subjects: 532
Study 24265159 — intervention group
Group type: COMPARATOR
Intervention: Morning administration of MTX/6MP
Number of subjects: 532
Study 21750293 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL-directed therapy (n = 84)
Number of subjects: 170
Study 21750293 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n = 86)
Number of subjects: 170
Study 19008239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 71
Study 18062758 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 157
Study 18062758 — intervention group
Group type: COMPARATOR
Intervention: Electric vacuum aspiration (EVA)
Number of subjects: 157
Study 15041599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular sufentanil 10 microg
Number of subjects: 60
Study 15041599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plus methylprednisolone 10 microg plus 40 mg
Number of subjects: 60
Study 15041599 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular saline (control)
Number of subjects: 60
Study 11149478 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g daily)
Number of subjects: 62
Study 11149478 — intervention group
Group type: COMPARATOR
Intervention: Low calorie diet without calcium supplementation
Number of subjects: 62
Study 9136944 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 490
Study 9136944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 490
Study 9136944 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan
Number of subjects: 490
Study 9136944 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk profile (Sokal)
Number of subjects: 490
Study 9136944 — intervention group
Group type: COMPARATOR
Intervention: Treatment groups
Number of subjects: 490
Study 8267186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 10 mg
Number of subjects: 0
Study 8267186 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 50 mg
Number of subjects: 0
Study 3318990 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 22
Study 3318990 — intervention group
Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 22
Study 30987432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg 3 times/d and hydration)
Number of subjects: 250
Study 30987432 — intervention group
Group type: COMPARATOR
Intervention: Control (hydration only)
Number of subjects: 250
Study 30987432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 250
Study 29696915 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Adalat 30 mg at 7 am daily for 6 weeks)
Number of subjects: 90
Study 29696915 — intervention group
Group type: EXPERIMENTAL
Intervention: No.1 acupuncture group (acupuncture technique for activating blood circulation, eliminating wind and regulating the liver and spleen, in addition to medication)
Number of subjects: 90
Study 29696915 — intervention group
Group type: EXPERIMENTAL
Intervention: No.2 acupuncture group (additional acupuncture at Fengchi (GB 20) and Neck‐Jiaji (EX‐B 2) on top of No.1 acupuncture group treatment)
Number of subjects: 90
Study 27761024 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose consumption
Number of subjects: 0
Study 27761024 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinhibited eating (characterized by reduced HRV)
Number of subjects: 0
Study 24914549 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg/day)
Number of subjects: 186
Study 24914549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 22352475 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-electrode stimulation with matched pulsing electrodes
Number of subjects: 7
Study 19933778 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer programme (Oportunidades)
Number of subjects: 979
Study 18442899 — intervention group
Group type: EXPERIMENTAL
Intervention: KNAVE‐II
Number of subjects: 120
Study 18442899 — intervention group
Group type: COMPARATOR
Intervention: Paper charts
Number of subjects: 120
Study 18442899 — intervention group
Group type: COMPARATOR
Intervention: ESS
Number of subjects: 120
Study 16160396 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-MRA
Number of subjects: 32
Study 12145715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment applied twice daily from admission to surgery
Number of subjects: 614
Study 12145715 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal ointment applied twice daily from admission to surgery
Number of subjects: 614
Study 12145715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 614
Study 12145715 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal ointment
Number of subjects: 614
Study 9990598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy (i.v. procainamide)
Number of subjects: 68
Study 9990598 — intervention group
Group type: COMPARATOR
Intervention: DC shock
Number of subjects: 68
Study 8520806 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible 46.5 mg (equivalent to 50 mg of diclofenac sodium)
Number of subjects: 60
Study 8520806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 60
Study 8520806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2315431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine HCl (15 mg twice daily)
Number of subjects: 0
Study 2315431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine HCl (single dose of 12.5 or 50 mg)
Number of subjects: 0
Study 2315431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine HCl (5‐20 mg once daily)
Number of subjects: 0
Study 2315431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6968220 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin (200 mg daily)
Number of subjects: 35
Study 6968220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (200 mg daily)
Number of subjects: 35
Study 6968220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6968220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (240 mg daily)
Number of subjects: 35
Study 6968220 — intervention group
Group type: COMPARATOR
Intervention: Wash-out period
Number of subjects: 35
Study 31533156 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electrostimulation (WB-EMS) with different electrical parameters
Number of subjects: 22
Study 31533156 — intervention group
Group type: COMPARATOR
Intervention: Resistance circuit training (control)
Number of subjects: 22
Study 28853971 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise interactive education intervention
Number of subjects: 160
Study 28853971 — intervention group
Group type: COMPARATOR
Intervention: General vaccination leaflet (Control)
Number of subjects: 160
Study 25576262 — intervention group
Group type: EXPERIMENTAL
Intervention: Water restriction trials
Number of subjects: 19
Study 25576262 — intervention group
Group type: COMPARATOR
Intervention: Water intake trials
Number of subjects: 19
Study 25576262 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise rehydration
Number of subjects: 19
Study 25576262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of Tosm and Posm
Number of subjects: 19
Study 23711804 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Number of subjects: 15526
Study 23711804 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 15526
Study 23711804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15526
Study 21840055 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (specific statins not detailed)
Number of subjects: 185
Study 21840055 — intervention group
Group type: COMPARATOR
Intervention: Nonadherence to medication
Number of subjects: 185
Study 21840055 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about medicines (assessed using BMQ-G)
Number of subjects: 185
Study 19675488 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation group (Group A)
Number of subjects: 4640
Study 19675488 — intervention group
Group type: COMPARATOR
Intervention: Validation group (Group B)
Number of subjects: 4640
Study 17585026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium acetate (NaAc)
Number of subjects: 8
Study 17585026 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 8
Study 14651448 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered planning processes
Number of subjects: 20
Study 14651448 — intervention group
Group type: COMPARATOR
Intervention: Traditional interdisciplinary service planning (ISP)
Number of subjects: 20
Study 11878726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg (7.5 mg ml(‐1))
Number of subjects: 72
Study 11878726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 100 mg (5 mg ml(‐1))
Number of subjects: 72
Study 11878726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 200 mg (10 mg ml(‐1))
Number of subjects: 72
Study 11878726 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 100 mg (5 mg ml(‐1))
Number of subjects: 72
Study 9751469 — intervention group
Group type: EXPERIMENTAL
Intervention: Static shoulder rotator endurance training
Number of subjects: 37
Study 9751469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic shoulder rotator endurance training
Number of subjects: 37
Study 7656632 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP system
Number of subjects: 7
Study 7656632 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP-NRV
Number of subjects: 7
Study 7656632 — intervention group
Group type: COMPARATOR
Intervention: CIPS (conventional intensive care ventilator)
Number of subjects: 7
Study 2744356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 30
Study 2744356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2744356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin injection
Number of subjects: 30
Study 333606 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and intraoperative antibiotics
Number of subjects: 1591
Study 333606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1591
Study 30904875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygopalatine ganglion pulsed radiofrequency (PRF) treatment at 42°C for 360 seconds
Number of subjects: 80
Study 30904875 — intervention group
Group type: COMPARATOR
Intervention: Nerve block (NB) treatment with a mixture of steroids and local anaesthetics
Number of subjects: 80
Study 30265305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility education (intervention group)
Number of subjects: 1455
Study 30265305 — intervention group
Group type: COMPARATOR
Intervention: Healthy pre-pregnancy information (control group 1)
Number of subjects: 1455
Study 30265305 — intervention group
Group type: COMPARATOR
Intervention: Family policies in Japan (control group 2)
Number of subjects: 1455
Study 27454855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Mediterranean-type meal (MMM)
Number of subjects: 28
Study 27454855 — intervention group
Group type: COMPARATOR
Intervention: High-saturated fatty acid meal (HSFAM)
Number of subjects: 28
Study 25361376 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic biofeedback
Number of subjects: 30
Study 25361376 — intervention group
Group type: COMPARATOR
Intervention: Bathroom scale training
Number of subjects: 30
Study 25361376 — intervention group
Group type: COMPARATOR
Intervention: Verbal instruction
Number of subjects: 30
Study 22498220 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 34887
Study 22498220 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 34887
Study 22498220 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E plus Selenium
Number of subjects: 34887
Study 22498220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34887
Study 20499024 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (500 mg vitamin C and 200 mg Tocovid)
Number of subjects: 64
Study 20499024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg)
Number of subjects: 64
Study 20499024 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol (200 mg)
Number of subjects: 64
Study 20499024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 17571481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 10mg
Number of subjects: 60
Study 17571481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 8mg + Fentanyl 20 microg
Number of subjects: 60
Study 17571481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 6mg + Fentanyl 20 microg
Number of subjects: 60
Study 16173084 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled clinician-initiated calls
Number of subjects: 44
Study 16173084 — intervention group
Group type: COMPARATOR
Intervention: Requested by the patient
Number of subjects: 44
Study 12574428 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural activity in a unique network involving bilateral dorsolateral prefrontal and posterior cortices
Number of subjects: 2
Study 12574428 — intervention group
Group type: COMPARATOR
Intervention: Left hemisphere network of regions including prefrontal and temporal cortices
Number of subjects: 2
Study 10333106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Drops (lyophilisate with HPMC)
Number of subjects: 32
Study 10333106 — intervention group
Group type: COMPARATOR
Intervention: Conventional eye drops (same polymer and electrolytes)
Number of subjects: 32
Study 8960830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Conventional Treatment (ICT)
Number of subjects: 91
Study 8960830 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 91
Study 1754635 — intervention group
Group type: EXPERIMENTAL
Intervention: ritanserin (5-10 mg)
Number of subjects: 10
Study 1754635 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 6923655 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin, 5000 IU s.c. every 8 hr for 7 days, first administration 2 hr before surgery
Number of subjects: 29
Study 6923655 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 29
Study 6709383 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal strategy treatment (response group) - trained to imagine pleasant scenes including muscular relaxation and deep breathing.
Number of subjects: 0
Study 6709383 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal strategy treatment (stimulus group) - trained to imagine scenes with many stimulus details.
Number of subjects: 0
Study 6709383 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 31852846 — intervention group
Group type: EXPERIMENTAL
Intervention: RN168 1 mg/kg every other week (Q2wk)
Number of subjects: 37
Study 31852846 — intervention group
Group type: EXPERIMENTAL
Intervention: RN168 3 mg/kg every other week (Q2wk)
Number of subjects: 37
Study 31852846 — intervention group
Group type: EXPERIMENTAL
Intervention: RN168 higher doses (not specified)
Number of subjects: 37
Study 30423846 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Pattern (HEP) cycling (Dietary Approaches to Stop Hypertension-style or Mediterranean-style)
Number of subjects: 60
Study 30423846 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Pattern (HEP) cycling
Number of subjects: 60
Study 26863596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy (ALA‐PDT)
Number of subjects: 93
Study 26863596 — intervention group
Group type: COMPARATOR
Intervention: Vehicle photodynamic therapy (VEH‐PDT)
Number of subjects: 93
Study 24997559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg for participants ≥18 years, 50 mg for those <18 years) and Lansoprazole (60 mg for participants ≥18 years, 30 mg for those <18 years)
Number of subjects: 68
Study 24997559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 22834121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladasten
Number of subjects: 0
Study 22834121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20139792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwear threshold of 90 minutes
Number of subjects: 107
Study 20139792 — intervention group
Group type: COMPARATOR
Intervention: Nonwear threshold of 60 minutes
Number of subjects: 107
Study 20139792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean daily activity counts
Number of subjects: 107
Study 20139792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean daily minutes of moderate to vigorous physical activity (MVPA)
Number of subjects: 107
Study 20139792 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA bout minutes per wear hour
Number of subjects: 107
Study 17932823 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine solution
Number of subjects: 114
Study 17932823 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 114
Study 16041592 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSE MRI
Number of subjects: 31